Guardant health inc..

May 9, 2023 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, “Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population” (Abstract #913e) showcasing the performance of its blood-based ...

Guardant health inc.. Things To Know About Guardant health inc..

Nov 29, 2023 · Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for ... Guardant Health to Appeal Federal District Court Verdict. November 15, 2023. PALO ALTO, Calif.-- (BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims ...Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer.Guardant Health expects full year 2023 revenue to be in the range of $525 million to $540 million, representing growth of 17% to 20% compared to full year 2022. …Guardant Health is a leading precision oncology company based in Palo Alto, California focused on helping conquer cancer globally through use of its ...

Guardant Health, Inc. must provide data from additional testing of clinical samples to supplement the analytical accuracy of Guardant360 CDx for biomarkers to be reported in the tumor profiling indication. Clinical samples should adequately represent the range of biomarkers that are detected by Guardant360"Guardant Health is at the cross section of technology and biology. The team brings many different skill sets from different industries, and we work in sync to achieve a common goal. I connected with the mission and could sense right away that I’d be happy working with, and learning from, this amazing pool of talented people.”

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for the Guardant Reveal™ molecular residual disease (MRD) …Aug 7, 2020 · Now FDA approved, the Guardant360 CDx delivers critical genomic information to oncologists from a simple blood draw. REDWOOD CITY, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved Guardant360 ® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic to select patients with unresectable (inoperable) advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2 ...Guardant Health is a leading precision oncology company based in Palo Alto, California focused on helping conquer cancer globally through use of its ...Earnings for Guardant Health are expected to grow in the coming year, from ($3.62) to ($3.33) per share. Guardant Health has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 22nd, 2024 based off prior year's report dates. Read More.PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to …

Source: Guardant Health, Inc. Contacts. Investor Contact: Alex Kleban [email protected] +1 657-254-5417 Media Contact: Michael Weist [email protected] +1 317-371-0035

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics.

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider Kumud Kalia sold 5,800 shares of the firm's stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $26.37, for a total transaction of $152,946.00. Following the completion of the transaction, the insider now owns 5,926 shares in the company, valued …Guardant Health, Inc. Redwood City, CA. 10. Yen J. BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy. Poster presented at: American Association for Cancer Research Annual Meeting. April 14-19, 2023: Orlando, FL. 11. Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts …PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of Guardant Galaxy TM, a suite of advanced analytical technologies developed internally and through outside partnerships to enhance the performance and clinical utility of Guardant Health’s …May 8, 2023 · PALO ALTO, Calif. – May 8, 2023 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief operating officer and the promotion of Darya Chudova to chief technology officer. “At Guardant, we have built one of the most ... PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco. The 10 poster presentations highlight the …Explore open positions at Guardant Health. 505 Penobscot Drive Redwood City, CA 94063. 855.698.8887. ONCOLOGY PORTAL LOGIN. GuardantGO SCREENING LOGIN. Our Approach. Our Commitment; For Patients; For Healthcare Providers; For Biopharma Partners; For Employers; Products. Tests for Cancer Screening;About Guardant Health. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower …

Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer February 16, 2021 Guardant Reveal ™ is industry’s first blood-only test able to detect, with 7-day turnaround time, residual disease after surgery and recurrence months earlier than ...At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.Founders AmirAli Talasaz, Helmy Eltoukhy. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Guardant Health, Inc. Stock Symbol NASDAQ:GH. Company Type For Profit. Contact Email [email protected]. Phone Number 650-290-7575. Guardant Health is committed to positively and significantly impacting patient health …May 22, 2023 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced that it has commenced an underwritten public offering of $250.0 million of its common stock. In addition, Guardant Health intends to grant the underwriters a 30-day option to purchase up to $37.5 million of its common ... PALO ALTO, Calif.-- (BUSINESS WIRE)-- Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has …ガーダントヘルスジャパン株式会社(英文表記:Guardant Health Japan Corp.) 設立: 2018年6月26日: 代表取締役 : シムランジット・シン: 代表取締役社長 : 高木 実加: 本社 〒105-7590 東京都港区海岸一丁目7番1号 東京ポートシティ竹芝オフィスタワー10F: ラボラト …

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today positive results from ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode), an over 20,000 patient registrational study evaluating the performance of its blood test for …

Mar 14, 2022 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360 ® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling, in patients with advanced solid tumors. Now FDA approved, the Guardant360 CDx delivers critical genomic information to oncologists from a simple blood draw. REDWOOD CITY, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has approved Guardant360 ® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients ...PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360 ® CDx liquid biopsy test as a companion diagnostic to identify advanced or metastatic breast cancer patients with …About Guardant Health. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower …See the latest Guardant Health Inc stock price (GH:XNAS), related news, valuation, dividends and more to help you make your investing decisions.May 6, 2021 · Achieved revenue of $78.7 million, driven by approximately 18,400 clinical tests. REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2021. Jun 30, 2023 · Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) June 30, 2023 . December 31, 2022 PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, “Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population” (Abstract #913e) showcasing the performance of its blood-based ...Important Note: The Guardant Reveal on Infinity test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.Guardant Reveal on Infinity …This letter serves as an annual notice on updates regarding the ordering and processing of clinical laboratory tests performed by Guardant Health, Inc. Guardant may update you more than once a year if there are material changes to the testing panel, such as FDA approval or a new product release. Please review the attached information in this ...

Guardant Health Inc (NASDAQ:GH), a leading precision oncology company, has recently witnessed a significant insider sell by its Chief Information Officer, …

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of …Product Overview. Guardant Infinity adapts and evolves with your data needs today and beyond. Choose from a range of applications, from measurable/minimal residual disease (MRD) and molecular response to therapy selection from insights on key Immuno-oncology (IO) and homologous repair deficiency (HRD) biomarkers.Guardant Health Files Lawsuit Against Natera for Misleading Oncologists. May 28, 2021. REDWOOD CITY, Calif.-- (BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today filed a lawsuit against Natera, Inc. for false advertising, unfair competition, and unlawful trade practices, relating to misleading ...Jan 30, 2023 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360 ® CDx liquid biopsy test as a companion diagnostic to identify advanced or metastatic breast cancer patients with ESR1 mutations who may benefit from treatment with ORSERDU™ (elacestrant ... Lincare Inc. sells oxygen and infusion systems for in-home respiratory therapy. Some of the oxygen systems include concentrators, portable and stationary liquid oxygen systems and high-pressure systems.PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today positive results from ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode), an over 20,000 patient registrational study evaluating the performance of its blood test for detecting colorectal ...PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023.505 Penobscot Dr. 855.698.8887. INVESTORS CAREERS SEARCH. PORTAL LOGIN. Learn how we are changing the future of cancer care. View all of our screening, early-stage cancer, and advanced cancer clinical studies. Read the latest news, announcements, and stories from Guardant Health. Get to know Guardant Health, our story, and our mission.

December 11, 2020. REDWOOD CITY, Calif.-- (BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Michael will succeed Derek Bertocci who has retired after successfully ushering the company through its ...Judge Burke's April Report also addressed motions brought by the parties in related case Guardant Health, Inc. v. Personal Genome Diagnostics, Inc ., C.A. No. 17-1623-LPS-CJB. That matter was dismissed on August 31, 2020, mooting the motions then pending in that action. ( See C.A. No. 17-1623-LPS-CJB D.I. 622)PALO ALTO, Calif., October 23, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that initial results from the PEGASUS trial suggest liquid biopsy may ...PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an expanded collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating its biopharmaceuticals business in the U.S. and Canada as EMD Serono, to …Instagram:https://instagram. o.n.ltsla stock chatjoint corpjeferies Feb 16, 2021 · REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the availability of Guardant Reveal™, the first blood-only liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw. 2 Specialities • 1 Doctor MON - TUE-THU - FRI 09:00AM - 2:00PM, 5:30PM - 7:30PM, SUN 09:00AM - 2:00PM how to short on robinhoodapple forecast Our Mission. Guardant Health AMEA is a wholly owned subsidiary of Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally … how to read option charts Hayward Pool Products Inc has been a leader in the swimming pool industry for over 90 years. Founded in 1925, Hayward has been committed to providing innovative and high-quality products for residential and commercial pools.We are passionate about serving patients and their families through the power of blood and the life-changing information it holds. Guardant Health is hiring bright minds in diverse fields to solve some of the most profound challenges in human health today. Learn more